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Glucocorticoids are considered the main treatment option for nasal polyps, but their effect is 
only recently being understood. 
Aim: To evaluate whether fluticasone propionate (FP) inhibits the inflammatory process induced by 
TNF-alpha in vitro, and to assess if NF-kappaB is associated to this inhibition. 
Study Design: Experimental in vitro study. 
Materials and Methods: Nasal polyp fibroblasts were cultured during 24 hours. Three different 
concentrations of FP (1, 10 and 100 nM, added to TNF-alpha) were compared to negative (without 
additive) and positive (TNF-alpha) controls. Gene expression (RTQ-PCR) and protein concentration 
(ELISA) of VCAM-1, ICAM-1, eotaxin and RANTES were measured, as well as the nuclear translocation 
of NF-kappaB. 
Results: TNF-alpha significantly increased protein concentration and RNA expression of all the 
studied molecules, as well as the nuclear translocation of NF-kappaB, when compared to the 
negative control. FP decreased these parameters in a dose-dependent manner, statistically different 
from positive control up to 100nM. 
Conclusions: FP extensively inhibited inflammatory recruiters, at both protein and RNA levels, 
confirming the ability of glucocorticoids to modulate the inflammatory process in nasal polyps. This 
inhibition was associated to decreased NF-kappaB nuclear translocation, demonstrating that this is 
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INTRODUCTION
Nasal polyps (NP) is an inflammatory disease, which 
primarily affects the sinonasal mucosa1,2. Inflammation is 
generally induced by pro-inflammatory cytokines, such as 
TNF-α (tumor necrosis factor-α) and IL-1β (interleukin-1β) 
and mediated by transcriptional factors (TF), such as NF-κβ 
(nuclear factor-κβ) and AP-1 (activator protein-1)3. Initially, 
TFs translocate into the nucleus and induce the expression 
of pro-inflammatory molecules in nasal structural cells (fi-
broblasts, epithelial and endothelial cells)3-7, which in turn 
produce chemokines and adhesion molecules (including 
eotaxin), RANTES (regulated upon activation normally T-
expressed and secreted), ICAM-1 (intercellular adhesion 
molecule-1), VCAM-1 (vascular cell adhesion molecule-1), 
E-selectin and P-selectin), that will induce the migration of 
inflammatory cells (such as T lymphocytes, eosinophils, 
mast cells, and neutrophils) towards the target7-9. Once 
on the nasal mucosa, the circulating cells will promote 
tissue damage8,10-12. Bachert et al.2 stated that deregula-
tion of chemokines and adhesion molecules production 
might be important in promoting the local chemotaxis of 
eosinophils.
According to the European Position Paper on Rhino-
sinusitis and Nasal Polyps 200711 and other researchers12-15, 
topical glucocorticoids (GC) are the cornerstone for treat-
ing NP. However, the success rate of topical GC ranges 
from 60.9 to 80%12,13,16. The anti-inflammatory property 
of GCs occurs due to their binding to the glucocorticoid 
receptor (GR); the GC-GR complex inhibits other TF, such 
as NF-κβ, a phenomenon known as transrepression4,17-19. 
The repression of NF-κβ will finally inhibit the expression 
of some cytokines as TNF-α, IL-1, IL-8 (interleukin-8) and 
ICAM-117. Transrepression between GCs and TFs is recip-
rocal, and NF-κβ17 can also repress glucocorticoid recep-
tors; which could, at least in part, induce GC resistance 
in some patients.
Recently20, our group has observed that in-vivo 
budesonide treatment leads to a significant improvement 
in symptoms and endoscopic reduction of nasal polyps. 
Despite this significant clinical improvement, only one pa-
tient reached complete remission. Moreover, we observed 
that patients with an unfavorable response to clinical treat-
ment presented higher levels of NF-κβ, ICAM-1 and IL-1β 
expression than before treatment21. Since NF-κβ induces 
transcription of both IL-1β and ICAM-1, we hypothesized 
that NF-κβ could be considered a pivotal mediator for the 
initiation of NP and resistance to GC. 
Thus, the aim of this study is to observe whether 
TNF-α induces the expression of inflammatory recruiters 
in polyp-derived fibroblasts, and whether fluticasone pro-
pionate (FP) inhibits this inflammatory response, in an in 
vitro model. Additionally, the mechanism by which this 
glucocorticoid acts was evaluated through protein and 
mRNA levels of VCAM-1, ICAM-1, eotaxin and RANTES, 
as well as by nuclear translocation of NF-κβ.
MATERIALS AND METHODS
The study delineation is summarized in Figure 1. 
Samples from six patients indicated to surgery after clini-
cal treatment failure were studied. For each case bilateral 
inflammatory NP was confirmed by CT scans and nasal 
endoscopy. Patients with associated systemic diseases 
such as ciliary dyskinesia, cystic fibrosis, AERD (aspirin 
exacerbated respiratory disease) or severe asthma were 
excluded. Prior to surgery all patients were kept free of 
any medication for one month. The present study was 
approved by the local IRB (process number 4374/2007).
Figure 1. Fluxogram of the study protocol
Cell culture
During the surgical procedure, a polyp biopsy was 
aseptically collected. The polyps were minced into 0.5 
mm fragments with surgical knife, and the fragments were 
then disaggregated with collagenase type IV for 2 hours. 
Following the enzymatic treatment, the cells were centri-
fuged and the collagenase solution removed and replaced 
with culture medium HAM-F10 (supplemented with 1% 
penicillin, 1% streptomycin, and 20% fetal calf serum), and 
cultured at 37oC in a 5% CO
2 
atmosphere.
After reaching 90% of confluence (one million 
cells/flask) the cells were trypsinized and the fibroblast 
component was confirmed by flow cytometry, following 
the protocol of Saalbach et al.22. 
Polyp cultures containing at least 90% fibroblasts 
were then replicated into 5 different flasks and after 24hs 
treated as follows: negative control (without additive), 
positive control (TNF-α 25ng/mL), FP1 (TNF-α 25ng/mL 
and FP 1nM/ 0.45μg/mL), FP10 (TNF-α 25ng/mL and FP 
10nM/4.5μg/mL) and FP100 (TNF-α 25 ng/mL and FP 
at 100nM/45μg/mL). These flasks, as their duplications, 
were incubated at 37oC in a 5% CO
2
 moist atmosphere 
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for another 24 hours. 
Treated cells were subsequently trypsinized and 
stored in Trizol® (for the study of RNAs) and DMSO (for 
nuclear extraction) at -80oC. The culture medium was 
stored at -20 oC for the ELISA study of the secreted mol-
ecules. Cell viability was confirmed to be higher than 90% 
through Trypan blue exclusion. 
Elisa
Protein concentration of eotaxin, RANTES, sICAM-1 
and sVCAM-1 was quantified in the culture medium by 
ELISA according to the manufacturer instructions (Bio-
source, CA, USA).
To normalize the results, the specific protein quanti-
fication was corrected according to total protein measured 
by the method of Bradford, as stated by Protein Assay-Bio 
Rad dye manufacturer.
PCR
RNA was extracted with Trizol®, and cDNAs were 
obtained with the High Capacity cDNA kit. The TaqMan® 
primers (Applied Biosystems) Hs00164932_m1 (ICAM-1), 
Hs00237013_m1 (eotaxin), Hs00174575_m1 (RANTES) and 
Hs00365486_m1 (VCAM-1), in addition to the housekeep-
ing Hs00266705_g1 (GAPDH), were used. The primer 
concentration was 900 nM and the TaqMan probe con-
centration was 300nM. 
Sample was diluted to 1:10, and 9μL of the dilution 
was added to 10μL Universal PCR Master Mix (Applied 
Biosystems) and 1μL of the probe. The 7500 Real-Time 
PCR System® was employed for analysis (PE Applied 
Biosystems). 
Each sample was tested in duplicate. In all reactions, 
the same negative controls and calibrators were amplified 
in parallel to determine the efficiency of all experiments. 
The threshold value of 0.1 was determined for gene 
study. Relative gene expression was quantified using the 
2-∆∆CT method and compared to GAPDH expression  in the 
same sample. The normalized value of each sample was 
then divided by the  calibrator, whose final expression 
value was assumed to be 1. 
Nuclear extraction
To evaluate the nuclear translocation of NF-kB, 
the cell membranes were ruptured and the nuclei were 
isolated as follows: cells were centrifuged at 16000g for 5 
minutes and washed twice in ice-cold PBS. Then, the pellet 
was incubated with ice-cold buffer A (10mmol/L HEPES, 
pH7.9, 10mmol/L KCl, 0.1mmol/L EDTA, 0.1mmol/L 
EGTA, 1mmol/L DTT, 1mg/L aprotinin, 1mg/L leupeptin, 
and 1mg/L pepstatin A) for 15 minutes. After cell mem-
brane lysis, 5μL 0.1% NP-40 was added and the solution 
was vigorously vortexed for 1 minute. The solution was 
then centrifuged at 20800g for 5 minutes at 4oC. The 
supernatant (corresponding to the cytoplasmic fraction) 
was discarded and the nuclear pellets were suspended 
in 50μL of ice-cold buffer B (20mmol/L HEPES, pH 7.9, 
420mmol/L NaCl, 0.1mmol/L EDTA, 0.1mmol/L EGTA, 
1mmol/L PMSF, 1mmol/L DTT, 1mg/L aprotinin, 1mg/L 
leupeptin, and 1mg/L  pepstatin). This new solution was 
kept at 4oC for 30 minutes with periodic vortexing and 
centrifuged at 20800g for 5 minutes at 4oC. The protein 
quantification of NF-κβ was performed in this final nuclei 
solution, through ELISA, as described above.
Statistical analysis
Results were analyzed by the Student t-test for 
paired samples, with the level of significance set at p<0.05.
RESULTS
Characterization of fibroblast cultures
After evaluating the viability of cells, a fraction was 
submitted to flow cytometry in order to confirm that the 
cultures were specifically composed by fibroblasts. Five 
of them displayed more than 98% positivity for CD90 
and less than 1% positive for CD34, confirming that they 
were almost exclusively fibroblasts. The other remaining 
sample presented only 92% of cells positive to CD90 and 
was excluded from the study.
Inflammatory recruiters - protein level
When compared to the negative control, TNF-α, at 
25ng/mL, significantly increased protein concentrations 
for ICAM-1 (3.17 fold ±0.77, p=0.0075), VCAM-1 (2.17 
fold ±0.66, p=0.0173), eotaxin (1.74 fold ±0.14, p=0.0003) 
and RANTES (4.78 fold ±1.57, p=0.0327) (Figures 2a to 
2d). FP decreased the inflammatory recruiters in a dose-
dependent manner for all the studied proteins (Figure 2). 
The reduction was significantly different from the positive 
control at all FP concentrations for eotaxin (p=0.0003) 
and RANTES (p=0.0327), for the 10 nM and 100nM FP 
treatments for sVCAM-1 (p=0.0402) and 100 nM of FP for 
sICAM-1 (p=0.0476). 
Additionally, protein concentrations of sVCAM-1 
and RANTES were statistically similar to the negative con-
trol at all FP concentrations. In contrast, sICAM-1 levels 
were significantly higher than the negative controls at all 
concentrations (p=0.0175 for FP 100nM) while eotaxin 
levels were significantly higher than negative control at FP 
1 and 10nM concentrations (p<0.0001 for 1nM and 0.0057 
for 10 nM), but reached similarity at the concentration of 
100nM.
Inflammatory recruiters - mRNA level
The expression of ICAM-1, VCAM-1, RANTES and 
eotaxin were analyzed though RTQ-PCR. Unfortunately, 
eotaxin expression was present only when fibroblasts 
were exposed to TNF-a, which impaired statistical analysis.
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TNF-α significantly increased mRNA expression of 
ICAM-1 (29.09 fold ±5.60, p=0.0004), VCAM-1 (10.22 fold 
±3.72, p=0.0052) and RANTES (31.62 fold ±8.72, p=0.0312) 
(Figure 3). Moreover, RTQ-PCR tests revealed that FP de-
creased their expression in a progressive manner (Figure 
3): the reduction was significantly different from the positi-
ve control at all FP concentrations for sVCAM-1 (p=0.0488) 
and for sICAM-1 (p=0.0368) and at concentrations higher 
than 10nM of FP for RANTES (p=0.0439). 
NF-κβ and increased expression of inflammatory recrui-
ters, we studied whether TNF-α and FP interfered with 
NF-κβ nuclear translocation. For this purpose, cells were 
submitted to nuclear extraction, and protein concentra-
tion of NF-κβ was measured in the nuclear fraction. The 
nuclear levels of this transcriptional factor also increased 
significantly when fibroblasts were exposed to positive 
stimulation (1.59 fold ±0.18, p=0.0018) (Figure 4). 
Figure 2. Protein levels of eotaxin, RANTES, VCAM-1 and ICAM-1 
measured by ELISA. All the relative values were compared to negative 
control (considered as 1.0).
Figure 3. mRNA expression (by RTQ-PCR) of VCAM-1, ICAM-1 and 
RANTES. All the relative values were compared to negative control 
(considered to be = 1.0).
In addition, the mRNA expression was similar to the 
negative controls at all FP concentrations for sICAM-1. In 
contrast, sVCAM-1 and RANTES expressions were signifi-
cantly higher compared to the negative controls at all the 
FP concentrations studied. 
Nuclear translocation of NF-κβ
Finally, to investigate a possible relation between 
Figure 4. Protein levels of nuclear NF-κβ measured by ELISA. All the 
relative values were compared to negative control (considered as 1.0).
Also, we assessed if FP reduced both mRNA and 
protein expression of adhesion molecules and chemokines 
due to NF-κβ inhibition. The ELISA experiment showed 
that FP significantly decreased NF-κβ translocation even 
at the lowest concentration (1nM) (p=0.0022). The levels 
of nuclear NF-κβ were statistically similar to those in the 
negative control for all FP concentrations (Figure 3).
DISCUSSION
The fibroblasts of nasal polyps, when induced by 
a variety of stimuli, can produce pro-inflammatory media-
tors. Meyer et al.23 compared the capacity of TNF-α, IL1-β 
or IFN-γ of increasing the expression of RANTES in nasal 
polyp fibroblasts and observed that TNF-α was a power-
ful pro-inflammatory stimulus. Based on this study, we 
chose TNF-α as the positive control for our experiment. 
We observed that fibroblasts habitually secrete VCAM-1, 
ICAM-1, eotaxin and RANTES in the culture medium and 
that TNF-α can significantly intensify the production of 
these mediators in fibroblasts cultures. 
Silvestri et al.7 assessed the effect of TNF-α and 
IL-4 on the expression of ICAM-1 and VCAM-1 by flow 
cytometry and on the secretion of eotaxin by ELISA in nasal 
polyp fibroblasts. The authors observed a significant in-
crease of ICAM-1 and eotaxin expression after 24 hours of 
exposure to progressive concentrations of TNF-α, although 
VCAM-1 levels remained stable. Similarly, Yoshifuku et al.24 
observed the effect of TNF-α and IL-4 on the expression 
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of eotaxin, RANTES and VCAM-1 in nasal polyp fibroblast 
using ELISA and demonstrated that TNF-α at the dose of 
10 ng/mL for 24 hours was able to induce the secretion 
of RANTES and VCAM-1, but not of eotaxin.
Ohori et al.25 reported that the expression of VCAM-1 
(evaluated by ELISA, flow cytometry and RT-PCR) in nasal 
fibroblasts was induced by TNF-α in a dose-dependent 
profile, with a peak at about 10 ng/mL, and reduced at next 
evaluated dose, 100 ng/mL. TNF-α also induced nuclear 
translocation and consequently activated NF-κβ.
We believe that the differences in expression of 
some chemokines or adhesion molecules may be re-
lated to the use of different concentrations of TNF-α, 
or to different techniques for the assessment of protein 
concentration and gene expression. However, there is 
agreement about the fact that, in general, TNF-α induces 
the expression of mRNA and the protein production of 
inflammatory recruiters. The data obtained in the present 
work are in accordance with this pattern of expression. 
We also observed that TNF-α significantly increased the 
nuclear translocation of NFκβ, confirming that this is an 
important mechanism of induction of pro-inflammatory 
mediators in NP, as stated by Ohori et al.25.
Thus, our results, as well as previous reports in lit-
erature, agree that the main mechanism in which TNF-α 
induces cytokines production is through activation of TFs. 
The TFs, when activated, translocate to the nucleus and 
interact with cell DNA, increasing the transcription of pro-
inflammatory genes.
The mechanism of action of GCs has not been fully 
elucidated, but its main anti-inflammatory effect is believed 
to be mediated by the inhibition of TFs 18,19. 
We observed that FP acts on nasal polyps fibro-
blasts, reducing the protein secretion and gene expres-
sion of inflammatory molecules. This reduction in the 
protein secretion was significantly different from positive 
control for RANTES and eotaxin at initial concentrations, 
and at higher concentrations of FP for ICAM-1. The pro-
tein production of VCAM-1 and RANTES remained quite 
similar to the observed for the negative control at all FP 
concentrations even though eotaxin and ICAM-1 presented 
concentrations significantly higher than control levels until 
treatment with 100nM of FP.
FP also significantly decreased gene expression of 
ICAM-1 and VCAM-1 at all FP concentrations, while RAN-
TES was significantly decreased after the 10nM treatment. 
However, the expression of RANTES was still significantly 
higher compared to negative control until 100nM of FP.
The present results are in agreement with those 
reported by Silvestri et al.7, who observed that FP in-
hibited eotaxin secretion by the fibroblasts starting at a 
low dose of 1 nM, whereas it inhibited ICAM-1 only at 
higher doses (10 nM).  Meyer et al.23 studied the effect of 
betamethasone and hydrocortisone on nasal fibroblasts, 
and demonstrated that these drugs were also effective in 
inhibiting the RANTES expression.
FP also significantly inhibited the nuclear transloca-
tion of NF-κB in fibroblasts at very low FP concentration. 
This effect on NF-κB in nasal polyp fibroblasts had already 
been suggested by Silvestri et al.7 and by our group21, al-
though this is the first in vitro study to confirm the effect 
of FP on NF-κB translocation for nasal polyps.
The mechanism of action of topical GCs on NP 
should be better recognized in order to improve the ef-
ficacy of clinical therapy for nasal polyps. New GCs, that 
specifically inhibit TFs, or TFs inhibitors, seem to be a 
reasonable rationale for new therapeutic approaches for 
this disease.
CONCLUSIONS
TNF-alpha significantly induced pro-inflammatory 
mediators production, both at mRNA and protein levels, 
in nasal polyps fibroblasts cultures.
Also, PF considerably decreased the mRNA and 
protein expression of all the pro-inflammatory mediators 
investigated in the present study. This inhibition in inflam-
matory process was related to a decrease in the nuclear 
translocation of NF-kappaB.
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